Table 2.
Seroprotection, seroconversion and titer in per-protocol population 30 days after the last vaccination.
| cIPV-tOPV-tOPV (n = 86) | cIPV-cIPV-cIPV (n = 82) | cIPV-bOPV-bOPV (n = 86) | tOPV-tOPV-tOPV (n = 78) | cIPV-cIPV-tOPV (n = 86) | cIPV-cIPV-bOPV (n = 86) | |
|---|---|---|---|---|---|---|
| Type 1 Poliovirus | ||||||
| Seroconversion | 84(97.67, 91.85–99.72) | 75(91.46, 83.20–96.50) | 85(98.84, 93.69–99.97) | 75(96.15, 89.17–99.20) | 81(94.19, 86.95–98.09) | 81(94.19, 86.95–98.09) |
| Seroconversion in susceptible infants | 55(100.0, 93.51–100.0) | 39(100.0, 90.97–100.0) | 40(100.0, 91.19–100.0) | 37(100.0, 90.51–100.0) | 41(100.0, 91.40–100.0) | 41(100.0, 91.40–100.0) |
| Seroconversion in non-susceptible infants | 29(93.55, 78.58–99.21) | 36(83.72, 69.30–93.19) | 45(97.83, 88.47–99.94) | 38(92.68, 80.08–98.46) | 40(88.89, 75.95–96.29) | 40(88.89, 75.95–96.29) |
| Seroprotection | 86(100.0, 95.80–100.0) | 82(100.0, 95.50–100.0) | 86(100.0, 95.80–100.0) | 78(100.0, 95.38–100.0) | 86(100.0, 95.80–100.0) | 85(98.84, 93.69–99.97) |
| GMT | 1100.89(875.60–1384.2) | 301.42(246.33–368.85) | 1822.01(1444.3–2298.5) | 1459.89(1124.9–1894.6) | 864.44(630.70–1184.9) | 1167.98(849.70–1605.5) |
| GMI | 133.04(94.64–340.06) | 28.89(20.43–40.86) | 161.66(116.63–224.07) | 153.98(106.49–222.65) | 86.55(58.05–129.04) | 107.46(69.83–165.39) |
| Type 2 Poliovirus | ||||||
| Seroconversion | 82(95.35, 88.52–98.72) | 70(85.37, 75.83–92.20) | 48(55.81, 44.70–66.52) | 76(97.44, 91.04–99.69) | 81(94.19, 86.95–98.09) | 71(82.56, 72.87–89.90) |
| Seroconversion in susceptible infants | 60(100.0, 94.04–100.0) | 54(100.0, 93.40–100.0) | 47(77.05, 64.50–86.85) | 41(100.0, 91.40–100.0) | 56(100.0, 93.62–100.0) | 63(100.0, 94.31–100.0) |
| Seroconversion in non-susceptible infants | 22(84.62, 65.13–95.64) | 16(57.14, 37.18–75.54) | 1(4.00, 0.10–20.35) | 35(94.59, 81.81–99.34) | 25(83.33, 65.28–94.36) | 8(34.78, 16.38–57.27) |
| Seroprotection | 85(98.84, 93.69–99.97) | 82(100.0, 95.60–100.0) | 59(68.60, 57.70–78.19) | 78(100.0, 95.38–100.0) | 86(100.0, 95.80–100.0) | 85(98.84, 93.69–99.97) |
| GMT | 279.19 (218.50–356.74) | 136.94(106.68–175.77) | 11.01(8.97–13.51) | 271.39(216.87–339.62) | 662.66(480.02–914.79) | 53.49(43.82–65.29) |
| GMI | 41.94 (30.60–57.50) | 19.70 (3.40–28.96) | 1.95 (1.48–2.57) | 36.43 (27.56–48.16) | 103.99 (69.92–154.66) | 8.76 (6.42–11.97) |
| Type 3 Poliovirus | ||||||
| Seroconversion | 82(95.35, 88.52–98.72) | 80(97.56, 91.47–99.70) | 85(98.84, 93.69–99.97) | 78(100.0, 95.38–100.0) | 86(100.0, 95.80–100.0) | 84(97.67, 91.85–99.72) |
| Seroconversion in susceptible infants | 70(97.22, 90.32–99.66) | 68(100.0, 94.72–100.0) | 77(98.72, 93.06–99.97) | 67(100.0, 94.64–100.0) | 76(100.0, 95.26–100.0) | 68(100.0, 94.72–100.0) |
| Seroconversion in non-susceptible infants | 12(85.71, 57.19–98.22) | 12(85.71, 57.19–98.22) | 8(100.0, 63.06–100.0) | 11(100.0, 71.51–100.0) | 10(100.0, 69.15–100.0) | 16(88.89, 65.29–98.62) |
| Seroprotection | 84(97.67, 91.85–99.72) | 82(100.0, 95.60–100.0) | 85(98.84, 93.69–99.97) | 78(100.0, 95.38–100.0) | 86(100.0, 95.80–100.0) | 86(100.0, 95.80–100.0) |
| GMT | 480.91 (359.04–644.15) | 370.52(293.54–467.68) | 698.14(565.37–862.09) | 477.11(382.39–595.31) | 777.98(575.70–1051.4) | 1068.89(755.90–1511.4) |
| GMI | 98.68(72.31–134.66) | 72.43(55.02–95.36) | 153.00(121.20–193.14) | 94.73(74.40–120.63) | 160.38(116.90–220.03) | 184.55(123.75–275.22) |
Data for seroprotection and seroconversion are n(%, 95%CI); data for titer are GMT(95%CI). 95%CI was estimated by exact test. Seroprotection defined as neutralizing titer of at least 8. For susceptible infants who were seronegative (titer<8),seroconversion was defined as achieving an antibody titer of at least 8; for non-susceptible infants who were seropositive (titer> = 8),seroconversionwas defined as a titer four times higher than the expected fall in maternal antibody concentrations based on the pre-vaccination titer. cIPV = conventional inactivated poliovirus vaccine. bOPV = bivalent oral poliovirus vaccine. tOPV = trivalent oral poliovirus vaccine. GMT = geometric mean reciprocal titer. GMI = fold increase in GMT.